Carani Sanjeevi
Director/Board Member at Allarity Therapeutics Europe ApS
Profile
Carani Sanjeevi is currently a Director at Allarity Therapeutics Europe ApS and a Professor at Karolinska Institutet since 2000.
He has formerly worked as a Director at Cadila Pharmaceuticals Sweden AB and Oncology Venture Sweden AB.
He was also an Independent Director at Allarity Therapeutics A from 2018 to 2020 and was the Head of the Molecular Immunogenetics Research Group at the Center for Molecular Medicine (Sweden).
Carani Sanjeevi active positions
| Companies | Position | Start |
|---|---|---|
| Karolinska Institutet | Corporate Officer/Principal | 1995-12-31 |
Allarity Therapeutics Europe ApS
 Allarity Therapeutics Europe ApS Pharmaceuticals: MajorHealth Technology Allarity Therapeutics Europe ApS operates as a pharmaceutical company that provides oncology products. The firm engages in diagnostics and drug development. The company was founded by Steen Meier Knudsen on August 1, 2012 and is headquartered in Hørsholm, Denmark. | Director/Board Member | - |
Former positions of Carani Sanjeevi
| Companies | Position | End |
|---|---|---|
Allarity Therapeutics A/S
 Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Director/Board Member | 2020-10-06 |
| Center for Molecular Medicine (Sweden) | Corporate Officer/Principal | - |
| Cadila Pharmaceuticals Sweden AB | Director/Board Member | - |
Oncology Venture Sweden AB
 Oncology Venture Sweden AB BiotechnologyHealth Technology Oncology Venture Sweden AB engages in research and development of anti-cancer drugs through its subsidiary Oncology Ventures ApS. It focuses on diagnostics and development of medicinal products for treatment of cancer. The company was founded by Peter Buhl Jensen, Steen Meier Knudsen, Nils Aage Brünner, and Ulla Hald Buhl on June 4, 2015 and is headquartered in Hørsholm, Denmark. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Oncology Venture Sweden AB
Oncology Venture Sweden AB BiotechnologyHealth Technology Oncology Venture Sweden AB engages in research and development of anti-cancer drugs through its subsidiary Oncology Ventures ApS. It focuses on diagnostics and development of medicinal products for treatment of cancer. The company was founded by Peter Buhl Jensen, Steen Meier Knudsen, Nils Aage Brünner, and Ulla Hald Buhl on June 4, 2015 and is headquartered in Hørsholm, Denmark. | Health Technology |
Allarity Therapeutics Europe ApS
Allarity Therapeutics Europe ApS Pharmaceuticals: MajorHealth Technology Allarity Therapeutics Europe ApS operates as a pharmaceutical company that provides oncology products. The firm engages in diagnostics and drug development. The company was founded by Steen Meier Knudsen on August 1, 2012 and is headquartered in Hørsholm, Denmark. | Health Technology |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Health Technology |
| Cadila Pharmaceuticals Sweden AB | Health Technology |
| Center for Molecular Medicine (Sweden) |
- Stock Market
- Insiders
- Carani Sanjeevi